

# Tyrosine Kinase JAK Inhibitors Industry Research Report 2024

<https://marketpublishers.com/r/T163E51AE725EN.html>

Date: April 2024

Pages: 129

Price: US\$ 2,950.00 (Single User License)

ID: T163E51AE725EN

## Abstracts

### Summary

Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.

These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.

In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.

According to APO Research, the global Tyrosine Kinase JAK Inhibitors market was valued at US\$ million in 2023 and is anticipated to reach US\$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.

North American market for Tyrosine Kinase JAK Inhibitors is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Tyrosine Kinase JAK Inhibitors is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Tyrosine Kinase JAK Inhibitors is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global manufacturers of Tyrosine Kinase JAK Inhibitors include Pfizer, Incyte, Novartis, Eli Lilly, Gilead, Sanofi, Galapagos, AbbVie and Vertex, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

## Report Scope

This report aims to provide a comprehensive presentation of the global market for Tyrosine Kinase JAK Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tyrosine Kinase JAK Inhibitors.

The report will help the Tyrosine Kinase JAK Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Tyrosine Kinase JAK Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue (\$ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tyrosine Kinase JAK Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

## Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to

the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Pfizer

Incyte

Novartis

Eli Lilly

Gilead

Sanofi

Galapagos

AbbVie

Vertex

Teva

Astellas Pharma

Celgene

CTI BioPharma

Tyrosine Kinase JAK Inhibitors segment by Type

Tofacitinib

Ruxolitinib

Baricitinib

## Tyrosine Kinase JAK Inhibitors segment by Application

Rheumatoid Arthritis (RA)

Polycythemia Vera (PCV)

Myelofibrosis (MF)

Others

## Tyrosine Kinase JAK Inhibitors Segment by Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

## Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

## Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tyrosine Kinase JAK Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tyrosine Kinase JAK Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tyrosine Kinase JAK Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

## Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Tyrosine Kinase JAK Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Tyrosine Kinase JAK Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Tyrosine Kinase JAK Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

## Contents

### 1 PREFACE

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
  - 1.5.1 Secondary Sources
  - 1.5.2 Primary Sources

### 2 MARKET OVERVIEW

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
  - 2.2.1 Global Tyrosine Kinase JAK Inhibitors Market Size (2019-2030) & (US\$ Million)
  - 2.2.2 Global Tyrosine Kinase JAK Inhibitors Sales (2019-2030)
  - 2.2.3 Global Tyrosine Kinase JAK Inhibitors Market Average Price (2019-2030)
- 2.3 Tyrosine Kinase JAK Inhibitors by Type
  - 2.3.1 Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US\$ Million)
  - 2.3.2 Tofacitinib
  - 2.3.3 Ruxolitinib
  - 2.3.4 Baricitinib
- 2.4 Tyrosine Kinase JAK Inhibitors by Application
  - 2.4.1 Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US\$ Million)
  - 2.4.2 Rheumatoid Arthritis (RA)
  - 2.4.3 Polycythemia Vera (PCV)
  - 2.4.4 Myelofibrosis (MF)
  - 2.4.5 Others

### 3 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS

- 3.1 Global Tyrosine Kinase JAK Inhibitors Market Competitive Situation by Manufacturers (2019 Versus 2023)
- 3.2 Global Tyrosine Kinase JAK Inhibitors Sales (K Units) of Manufacturers (2019-2024)
- 3.3 Global Tyrosine Kinase JAK Inhibitors Revenue of Manufacturers (2019-2024)
- 3.4 Global Tyrosine Kinase JAK Inhibitors Average Price by Manufacturers (2019-2024)



- 3.5 Global Tyrosine Kinase JAK Inhibitors Industry Ranking, 2022 VS 2023 VS 2024
- 3.6 Global Manufacturers of Tyrosine Kinase JAK Inhibitors, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Tyrosine Kinase JAK Inhibitors, Product Type & Application
- 3.8 Global Manufacturers of Tyrosine Kinase JAK Inhibitors, Date of Enter into This Industry
- 3.9 Global Tyrosine Kinase JAK Inhibitors Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

## **4 MANUFACTURERS PROFILED**

### 4.1 Pfizer

- 4.1.1 Pfizer Company Information
- 4.1.2 Pfizer Business Overview
- 4.1.3 Pfizer Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
- 4.1.4 Pfizer Tyrosine Kinase JAK Inhibitors Product Portfolio
- 4.1.5 Pfizer Recent Developments

### 4.2 Incyte

- 4.2.1 Incyte Company Information
- 4.2.2 Incyte Business Overview
- 4.2.3 Incyte Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
- 4.2.4 Incyte Tyrosine Kinase JAK Inhibitors Product Portfolio
- 4.2.5 Incyte Recent Developments

### 4.3 Novartis

- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
- 4.3.4 Novartis Tyrosine Kinase JAK Inhibitors Product Portfolio
- 4.3.5 Novartis Recent Developments

### 4.4 Eli Lilly

- 4.4.1 Eli Lilly Company Information
- 4.4.2 Eli Lilly Business Overview
- 4.4.3 Eli Lilly Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
- 4.4.4 Eli Lilly Tyrosine Kinase JAK Inhibitors Product Portfolio
- 4.4.5 Eli Lilly Recent Developments

#### 4.5 Gilead

4.5.1 Gilead Company Information

4.5.2 Gilead Business Overview

4.5.3 Gilead Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin  
(2019-2024)

4.5.4 Gilead Tyrosine Kinase JAK Inhibitors Product Portfolio

4.5.5 Gilead Recent Developments

#### 4.6 Sanofi

4.6.1 Sanofi Company Information

4.6.2 Sanofi Business Overview

4.6.3 Sanofi Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin  
(2019-2024)

4.6.4 Sanofi Tyrosine Kinase JAK Inhibitors Product Portfolio

4.6.5 Sanofi Recent Developments

#### 4.7 Galapagos

4.7.1 Galapagos Company Information

4.7.2 Galapagos Business Overview

4.7.3 Galapagos Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin  
(2019-2024)

4.7.4 Galapagos Tyrosine Kinase JAK Inhibitors Product Portfolio

4.7.5 Galapagos Recent Developments

#### 4.8 AbbVie

4.8.1 AbbVie Company Information

4.8.2 AbbVie Business Overview

4.8.3 AbbVie Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin  
(2019-2024)

4.8.4 AbbVie Tyrosine Kinase JAK Inhibitors Product Portfolio

4.8.5 AbbVie Recent Developments

#### 4.9 Vertex

4.9.1 Vertex Company Information

4.9.2 Vertex Business Overview

4.9.3 Vertex Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin  
(2019-2024)

4.9.4 Vertex Tyrosine Kinase JAK Inhibitors Product Portfolio

4.9.5 Vertex Recent Developments

#### 4.10 Teva

4.10.1 Teva Company Information

4.10.2 Teva Business Overview

4.10.3 Teva Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin

(2019-2024)

4.10.4 Teva Tyrosine Kinase JAK Inhibitors Product Portfolio

4.10.5 Teva Recent Developments

4.11 Astellas Pharma

4.11.1 Astellas Pharma Company Information

4.11.2 Astellas Pharma Business Overview

4.11.3 Astellas Pharma Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)

4.11.4 Astellas Pharma Tyrosine Kinase JAK Inhibitors Product Portfolio

4.11.5 Astellas Pharma Recent Developments

4.12 Celgene

4.12.1 Celgene Company Information

4.12.2 Celgene Business Overview

4.12.3 Celgene Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin

(2019-2024)

4.12.4 Celgene Tyrosine Kinase JAK Inhibitors Product Portfolio

4.12.5 Celgene Recent Developments

4.13 CTI BioPharma

4.13.1 CTI BioPharma Company Information

4.13.2 CTI BioPharma Business Overview

4.13.3 CTI BioPharma Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)

4.13.4 CTI BioPharma Tyrosine Kinase JAK Inhibitors Product Portfolio

4.13.5 CTI BioPharma Recent Developments

## **5 GLOBAL TYROSINE KINASE JAK INHIBITORS MARKET SCENARIO BY REGION**

5.1 Global Tyrosine Kinase JAK Inhibitors Market Size by Region: 2019 VS 2023 VS 2030

5.2 Global Tyrosine Kinase JAK Inhibitors Sales by Region: 2019-2030

5.2.1 Global Tyrosine Kinase JAK Inhibitors Sales by Region: 2019-2024

5.2.2 Global Tyrosine Kinase JAK Inhibitors Sales by Region: 2025-2030

5.3 Global Tyrosine Kinase JAK Inhibitors Revenue by Region: 2019-2030

5.3.1 Global Tyrosine Kinase JAK Inhibitors Revenue by Region: 2019-2024

5.3.2 Global Tyrosine Kinase JAK Inhibitors Revenue by Region: 2025-2030

5.4 North America Tyrosine Kinase JAK Inhibitors Market Facts & Figures by Country

5.4.1 North America Tyrosine Kinase JAK Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

5.4.2 North America Tyrosine Kinase JAK Inhibitors Sales by Country (2019-2030)

#### 5.4.3 North America Tyrosine Kinase JAK Inhibitors Revenue by Country (2019-2030)

##### 5.4.4 U.S.

##### 5.4.5 Canada

#### 5.5 Europe Tyrosine Kinase JAK Inhibitors Market Facts & Figures by Country

##### 5.5.1 Europe Tyrosine Kinase JAK Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

##### 5.5.2 Europe Tyrosine Kinase JAK Inhibitors Sales by Country (2019-2030)

##### 5.5.3 Europe Tyrosine Kinase JAK Inhibitors Revenue by Country (2019-2030)

##### 5.5.4 Germany

##### 5.5.5 France

##### 5.5.6 U.K.

##### 5.5.7 Italy

##### 5.5.8 Russia

#### 5.6 Asia Pacific Tyrosine Kinase JAK Inhibitors Market Facts & Figures by Country

##### 5.6.1 Asia Pacific Tyrosine Kinase JAK Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

##### 5.6.2 Asia Pacific Tyrosine Kinase JAK Inhibitors Sales by Country (2019-2030)

##### 5.6.3 Asia Pacific Tyrosine Kinase JAK Inhibitors Revenue by Country (2019-2030)

##### 5.6.4 China

##### 5.6.5 Japan

##### 5.6.6 South Korea

##### 5.6.7 India

##### 5.6.8 Australia

##### 5.6.9 China Taiwan

##### 5.6.10 Indonesia

##### 5.6.11 Thailand

##### 5.6.12 Malaysia

#### 5.7 Latin America Tyrosine Kinase JAK Inhibitors Market Facts & Figures by Country

##### 5.7.1 Latin America Tyrosine Kinase JAK Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

##### 5.7.2 Latin America Tyrosine Kinase JAK Inhibitors Sales by Country (2019-2030)

##### 5.7.3 Latin America Tyrosine Kinase JAK Inhibitors Revenue by Country (2019-2030)

##### 5.7.4 Mexico

##### 5.7.5 Brazil

##### 5.7.6 Argentina

#### 5.8 Middle East and Africa Tyrosine Kinase JAK Inhibitors Market Facts & Figures by Country

##### 5.8.1 Middle East and Africa Tyrosine Kinase JAK Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

5.8.2 Middle East and Africa Tyrosine Kinase JAK Inhibitors Sales by Country (2019-2030)

5.8.3 Middle East and Africa Tyrosine Kinase JAK Inhibitors Revenue by Country (2019-2030)

5.8.4 Turkey

5.8.5 Saudi Arabia

5.8.6 UAE

## **6 SEGMENT BY TYPE**

6.1 Global Tyrosine Kinase JAK Inhibitors Sales by Type (2019-2030)

6.1.1 Global Tyrosine Kinase JAK Inhibitors Sales by Type (2019-2030) & (K Units)

6.1.2 Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Type (2019-2030)

6.2 Global Tyrosine Kinase JAK Inhibitors Revenue by Type (2019-2030)

6.2.1 Global Tyrosine Kinase JAK Inhibitors Sales by Type (2019-2030) & (US\$ Million)

6.2.2 Global Tyrosine Kinase JAK Inhibitors Revenue Market Share by Type (2019-2030)

6.3 Global Tyrosine Kinase JAK Inhibitors Price by Type (2019-2030)

## **7 SEGMENT BY APPLICATION**

7.1 Global Tyrosine Kinase JAK Inhibitors Sales by Application (2019-2030)

7.1.1 Global Tyrosine Kinase JAK Inhibitors Sales by Application (2019-2030) & (K Units)

7.1.2 Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Application (2019-2030)

7.2 Global Tyrosine Kinase JAK Inhibitors Revenue by Application (2019-2030)

7.2.1 Global Tyrosine Kinase JAK Inhibitors Sales by Application (2019-2030) & (US\$ Million)

7.2.2 Global Tyrosine Kinase JAK Inhibitors Revenue Market Share by Application (2019-2030)

7.3 Global Tyrosine Kinase JAK Inhibitors Price by Application (2019-2030)

## **8 VALUE CHAIN AND SALES CHANNELS ANALYSIS OF THE MARKET**

8.1 Tyrosine Kinase JAK Inhibitors Value Chain Analysis

8.1.1 Tyrosine Kinase JAK Inhibitors Key Raw Materials

8.1.2 Raw Materials Key Suppliers

- 8.1.3 Tyrosine Kinase JAK Inhibitors Production Mode & Process
- 8.2 Tyrosine Kinase JAK Inhibitors Sales Channels Analysis
  - 8.2.1 Direct Comparison with Distribution Share
  - 8.2.2 Tyrosine Kinase JAK Inhibitors Distributors
  - 8.2.3 Tyrosine Kinase JAK Inhibitors Customers

## **9 GLOBAL TYROSINE KINASE JAK INHIBITORS ANALYZING MARKET DYNAMICS**

- 9.1 Tyrosine Kinase JAK Inhibitors Industry Trends
- 9.2 Tyrosine Kinase JAK Inhibitors Industry Drivers
- 9.3 Tyrosine Kinase JAK Inhibitors Industry Opportunities and Challenges
- 9.4 Tyrosine Kinase JAK Inhibitors Industry Restraints

## **10 REPORT CONCLUSION**

## **11 DISCLAIMER**

## List Of Tables

### LIST OF TABLES

Table 1. Secondary Sources

Table 2. Primary Sources

Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US\$ Million)

Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US\$ Million)

Table 5. Global Tyrosine Kinase JAK Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2018 Versus 2022)

Table 6. Global Tyrosine Kinase JAK Inhibitors Sales (K Units) of Manufacturers (2018-2023)

Table 7. Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Manufacturers (2018-2023)

Table 8. Global Tyrosine Kinase JAK Inhibitors Revenue of Manufacturers (2018-2023)

Table 9. Global Tyrosine Kinase JAK Inhibitors Revenue Share by Manufacturers (2018-2023)

Table 10. Global Market Tyrosine Kinase JAK Inhibitors Average Price (USD/Unit) of Manufacturers (2018-2023)

Table 11. Global Tyrosine Kinase JAK Inhibitors Industry Ranking, 2021 VS 2022 VS 2023

Table 12. Global Manufacturers of Tyrosine Kinase JAK Inhibitors, Product Type & Application

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Tyrosine Kinase JAK Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans)

Table 16. Pfizer Company Information

Table 17. Pfizer Business Overview

Table 18. Pfizer Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 19. Pfizer Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 20. Pfizer Recent Developments

Table 21. Incyte Company Information

Table 22. Incyte Business Overview

Table 23. Incyte Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 24. Incyte Tyrosine Kinase JAK Inhibitors Product Portfolio

- Table 25. Incyte Recent Developments
- Table 26. Novartis Company Information
- Table 27. Novartis Business Overview
- Table 28. Novartis Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
- Table 29. Novartis Tyrosine Kinase JAK Inhibitors Product Portfolio
- Table 30. Novartis Recent Developments
- Table 31. Eli Lilly Company Information
- Table 32. Eli Lilly Business Overview
- Table 33. Eli Lilly Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
- Table 34. Eli Lilly Tyrosine Kinase JAK Inhibitors Product Portfolio
- Table 35. Eli Lilly Recent Developments
- Table 36. Gilead Company Information
- Table 37. Gilead Business Overview
- Table 38. Gilead Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
- Table 39. Gilead Tyrosine Kinase JAK Inhibitors Product Portfolio
- Table 40. Gilead Recent Developments
- Table 41. Sanofi Company Information
- Table 42. Sanofi Business Overview
- Table 43. Sanofi Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
- Table 44. Sanofi Tyrosine Kinase JAK Inhibitors Product Portfolio
- Table 45. Sanofi Recent Developments
- Table 46. Galapagos Company Information
- Table 47. Galapagos Business Overview
- Table 48. Galapagos Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
- Table 49. Galapagos Tyrosine Kinase JAK Inhibitors Product Portfolio
- Table 50. Galapagos Recent Developments
- Table 51. AbbVie Company Information
- Table 52. AbbVie Business Overview
- Table 53. AbbVie Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
- Table 54. AbbVie Tyrosine Kinase JAK Inhibitors Product Portfolio
- Table 55. AbbVie Recent Developments
- Table 56. Vertex Company Information
- Table 57. Vertex Business Overview



Table 58. Vertex Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 59. Vertex Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 60. Vertex Recent Developments

Table 61. Teva Company Information

Table 62. Teva Business Overview

Table 63. Teva Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 64. Teva Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 65. Teva Recent Developments

Table 66. Astellas Pharma Company Information

Table 67. Astellas Pharma Business Overview

Table 68. Astellas Pharma Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 69. Astellas Pharma Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 70. Astellas Pharma Recent Developments

Table 71. Celgene Company Information

Table 72. Celgene Business Overview

Table 73. Celgene Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 74. Celgene Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 75. Celgene Recent Developments

Table 76. CTI BioPharma Company Information

Table 77. CTI BioPharma Business Overview

Table 78. CTI BioPharma Tyrosine Kinase JAK Inhibitors Sales (K Units), Revenue (US\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 79. CTI BioPharma Tyrosine Kinase JAK Inhibitors Product Portfolio

Table 80. CTI BioPharma Recent Developments

Table 81. Global Tyrosine Kinase JAK Inhibitors Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 82. Global Tyrosine Kinase JAK Inhibitors Sales by Region (2018-2023) & (K Units)

Table 83. Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Region (2018-2023)

Table 84. Global Tyrosine Kinase JAK Inhibitors Sales by Region (2024-2029) & (K Units)

Table 85. Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Region (2024-2029)

Table 86. Global Tyrosine Kinase JAK Inhibitors Revenue by Region (2018-2023) &

(US\$ Million)

Table 87. Global Tyrosine Kinase JAK Inhibitors Revenue Market Share by Region (2018-2023)

Table 88. Global Tyrosine Kinase JAK Inhibitors Revenue by Region (2024-2029) & (US\$ Million)

Table 89. Global Tyrosine Kinase JAK Inhibitors Revenue Market Share by Region (2024-2029)

Table 90. North America Tyrosine Kinase JAK Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 91. North America Tyrosine Kinase JAK Inhibitors Sales by Country (2018-2023) & (K Units)

Table 92. North America Tyrosine Kinase JAK Inhibitors Sales by Country (2024-2029) & (K Units)

Table 93. North America Tyrosine Kinase JAK Inhibitors Revenue by Country (2018-2023) & (US\$ Million)

Table 94. North America Tyrosine Kinase JAK Inhibitors Revenue by Country (2024-2029) & (US\$ Million)

Table 95. Europe Tyrosine Kinase JAK Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 96. Europe Tyrosine Kinase JAK Inhibitors Sales by Country (2018-2023) & (K Units)

Table 97. Europe Tyrosine Kinase JAK Inhibitors Sales by Country (2024-2029) & (K Units)

Table 98. Europe Tyrosine Kinase JAK Inhibitors Revenue by Country (2018-2023) & (US\$ Million)

Table 99. Europe Tyrosine Kinase JAK Inhibitors Revenue by Country (2024-2029) & (US\$ Million)

Table 100. Asia Pacific Tyrosine Kinase JAK Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 101. Asia Pacific Tyrosine Kinase JAK Inhibitors Sales by Country (2018-2023) & (K Units)

Table 102. Asia Pacific Tyrosine Kinase JAK Inhibitors Sales by Country (2024-2029) & (K Units)

Table 103. Asia Pacific Tyrosine Kinase JAK Inhibitors Revenue by Country (2018-2023) & (US\$ Million)

Table 104. Asia Pacific Tyrosine Kinase JAK Inhibitors Revenue by Country (2024-2029) & (US\$ Million)

Table 105. Latin America Tyrosine Kinase JAK Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 106. Latin America Tyrosine Kinase JAK Inhibitors Sales by Country (2018-2023) & (K Units)

Table 107. Latin America Tyrosine Kinase JAK Inhibitors Sales by Country (2024-2029) & (K Units)

Table 108. Latin America Tyrosine Kinase JAK Inhibitors Revenue by Country (2018-2023) & (US\$ Million)

Table 109. Latin America Tyrosine Kinase JAK Inhibitors Revenue by Country (2024-2029) & (US\$ Million)

Table 110. Middle East and Africa Tyrosine Kinase JAK Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 111. Middle East and Africa Tyrosine Kinase JAK Inhibitors Sales by Country (2018-2023) & (K Units)

Table 112. Middle East and Africa Tyrosine Kinase JAK Inhibitors Sales by Country (2024-2029) & (K Units)

Table 113. Middle East and Africa Tyrosine Kinase JAK Inhibitors Revenue by Country (2018-2023) & (US\$ Million)

Table 114. Middle East and Africa Tyrosine Kinase JAK Inhibitors Revenue by Country (2024-2029) & (US\$ Million)

Table 115. Global Tyrosine Kinase JAK Inhibitors Sales by Type (2018-2023) & (K Units)

Table 116. Global Tyrosine Kinase JAK Inhibitors Sales by Type (2024-2029) & (K Units)

Table 117. Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Type (2018-2023)

Table 118. Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Type (2024-2029)

Table 119. Global Tyrosine Kinase JAK Inhibitors Revenue by Type (2018-2023) & (US\$ Million)

Table 120. Global Tyrosine Kinase JAK Inhibitors Revenue by Type (2024-2029) & (US\$ Million)

Table 121. Global Tyrosine Kinase JAK Inhibitors Revenue Market Share by Type (2018-2023)

Table 122. Global Tyrosine Kinase JAK Inhibitors Revenue Market Share by Type (2024-2029)

Table 123. Global Tyrosine Kinase JAK Inhibitors Price by Type (2018-2023) & (USD/Unit)

Table 124. Global Tyrosine Kinase JAK Inhibitors Price by Type (2024-2029) & (USD/Unit)

Table 125. Global Tyrosine Kinase JAK Inhibitors Sales by Application (2018-2023) &

(K Units)

Table 126. Global Tyrosine Kinase JAK Inhibitors Sales by Application (2024-2029) & (K Units)

Table 127. Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Application (2018-2023)

Table 128. Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Application (2024-2029)

Table 129. Global Tyrosine Kinase JAK Inhibitors Revenue by Application (2018-2023) & (US\$ Million)

Table 130. Global Tyrosine Kinase JAK Inhibitors Revenue by Application (2024-2029) & (US\$ Million)

Table 131. Global Tyrosine Kinase JAK Inhibitors Revenue Market Share by Application (2018-2023)

Table 132. Global Tyrosine Kinase JAK Inhibitors Revenue Market Share by Application (2024-2029)

Table 133. Global Tyrosine Kinase JAK Inhibitors Price by Application (2018-2023) & (USD/Unit)

Table 134. Global Tyrosine Kinase JAK Inhibitors Price by Application (2024-2029) & (USD/Unit)

Table 135. Key Raw Materials

Table 136. Raw Materials Key Suppliers

Table 137. Tyrosine Kinase JAK Inhibitors Distributors List

Table 138. Tyrosine Kinase JAK Inhibitors Customers List

Table 139. Tyrosine Kinase JAK Inhibitors Industry Trends

Table 140. Tyrosine Kinase JAK Inhibitors Industry Drivers

Table 141. Tyrosine Kinase JAK Inhibitors Industry Restraints

Table 142. Authors List of This Report

## List Of Figures

### LIST OF FIGURES

Figure 1. Research Methodology

Figure 2. Research Process

Figure 3. Key Executives Interviewed

Figure 4. Tyrosine Kinase JAK Inhibitors Product Picture

Figure 5. Global Tyrosine Kinase JAK Inhibitors Revenue (US\$ Million), 2018 VS 2022 VS 2029

Figure 6. Global Tyrosine Kinase JAK Inhibitors Market Size (2018-2029) & (US\$ Million)

Figure 7. Global Tyrosine Kinase JAK Inhibitors Sales (2018-2029) & (K Units)

Figure 8. Global Tyrosine Kinase JAK Inhibitors Average Price (USD/Unit) & (2018-2029)

Figure 9. Tofacitinib Product Picture

Figure 10. Ruxolitinib Product Picture

Figure 11. Baricitinib Product Picture

Figure 12. Rheumatoid Arthritis (RA) Product Picture

Figure 13. Polycythemia Vera (PCV) Product Picture

Figure 14. Myelofibrosis (MF) Product Picture

Figure 15. Others Product Picture

Figure 16. Global Tyrosine Kinase JAK Inhibitors Revenue Share by Manufacturers in 2022

Figure 17. Global Manufacturers of Tyrosine Kinase JAK Inhibitors, Manufacturing Sites & Headquarters

Figure 18. Global Manufacturers of Tyrosine Kinase JAK Inhibitors, Date of Enter into This Industry

Figure 19. Global Top 5 and 10 Tyrosine Kinase JAK Inhibitors Players Market Share by Revenue in 2022

Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022

Figure 21. Global Tyrosine Kinase JAK Inhibitors Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Figure 22. Global Tyrosine Kinase JAK Inhibitors Sales by Region in 2022

Figure 23. Global Tyrosine Kinase JAK Inhibitors Revenue by Region in 2022

Figure 24. North America Tyrosine Kinase JAK Inhibitors Market Size by Country in 2022

Figure 25. North America Tyrosine Kinase JAK Inhibitors Sales Market Share by Country (2018-2029)

Figure 26. North America Tyrosine Kinase JAK Inhibitors Revenue Market Share by Country (2018-2029)

Figure 27. U.S. Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 28. Canada Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 29. Europe Tyrosine Kinase JAK Inhibitors Market Size by Country in 2022

Figure 30. Europe Tyrosine Kinase JAK Inhibitors Sales Market Share by Country (2018-2029)

Figure 31. Europe Tyrosine Kinase JAK Inhibitors Revenue Market Share by Country (2018-2029)

Figure 32. Germany Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 33. France Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 34. U.K. Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 35. Italy Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 36. Russia Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 37. Asia Pacific Tyrosine Kinase JAK Inhibitors Market Size by Country in 2022

Figure 38. Asia Pacific Tyrosine Kinase JAK Inhibitors Sales Market Share by Country (2018-2029)

Figure 39. Asia Pacific Tyrosine Kinase JAK Inhibitors Revenue Market Share by Country (2018-2029)

Figure 40. China Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 41. Japan Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 42. South Korea Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 43. India Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 44. Australia Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 45. China Taiwan Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 46. Indonesia Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029)

& (US\$ Million)

Figure 47. Thailand Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029)

& (US\$ Million)

Figure 48. Malaysia Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029)

& (US\$ Million)

Figure 49. Latin America Tyrosine Kinase JAK Inhibitors Market Size by Country in 2022

Figure 50. Latin America Tyrosine Kinase JAK Inhibitors Sales Market Share by Country (2018-2029)

Figure 51. Latin America Tyrosine Kinase JAK Inhibitors Revenue Market Share by Country (2018-2029)

Figure 52. Mexico Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 53. Brazil Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 54. Argentina Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 55. Middle East and Africa Tyrosine Kinase JAK Inhibitors Market Size by Country in 2022

Figure 56. Middle East and Africa Tyrosine Kinase JAK Inhibitors Sales Market Share by Country (2018-2029)

Figure 57. Middle East and Africa Tyrosine Kinase JAK Inhibitors Revenue Market Share by Country (2018-2029)

Figure 58. Turkey Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 59. Saudi Arabia Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 60. UAE Tyrosine Kinase JAK Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 61. Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Type (2018-2029)

Figure 62. Global Tyrosine Kinase JAK Inhibitors Revenue Market Share by Type (2018-2029)

Figure 63. Global Tyrosine Kinase JAK Inhibitors Price (USD/Unit) by Type (2018-2029)

Figure 64. Global Tyrosine Kinase JAK Inhibitors Sales Market Share by Application (2018-2029)

Figure 65. Global Tyrosine Kinase JAK Inhibitors Revenue Market Share by Application (2018-2029)

Figure 66. Global Tyrosine Kinase JAK Inhibitors Price (USD/Unit) by Application

(2018-2029)

Figure 67. Tyrosine Kinase JAK Inhibitors Value Chain

Figure 68. Tyrosine Kinase JAK Inhibitors Production Mode & Process

Figure 69. Direct Comparison with Distribution Share

Figure 70. Distributors Profiles

Figure 71. Tyrosine Kinase JAK Inhibitors Industry Opportunities and Challenges



## I would like to order

Product name: Tyrosine Kinase JAK Inhibitors Industry Research Report 2024

Product link: <https://marketpublishers.com/r/T163E51AE725EN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T163E51AE725EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970